New Zealand markets closed

VYNE Therapeutics Inc. (VYNE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.6200+0.1200 (+4.80%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 35.25M
Enterprise value -57.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)60.57
Price/book (mrq)0.40
Enterprise value/revenue -136.30
Enterprise value/EBITDA 1.98

Trading information

Stock price history

Beta (5Y monthly) 1.46
52-week change 3-68.59%
S&P500 52-week change 322.43%
52-week high 38.7300
52-week low 31.6700
50-day moving average 32.4633
200-day moving average 33.0915

Share statistics

Avg vol (3-month) 3103.55k
Avg vol (10-day) 372.47k
Shares outstanding 514.1M
Implied shares outstanding 614.1M
Float 89.45M
% held by insiders 18.69%
% held by institutions 159.21%
Shares short (15 Apr 2024) 496.83k
Short ratio (15 Apr 2024) 40.59
Short % of float (15 Apr 2024) 40.69%
Short % of shares outstanding (15 Apr 2024) 40.69%
Shares short (prior month 15 Mar 2024) 412.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:18
Last split date 313 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-8,989.47%

Management effectiveness

Return on assets (ttm)-26.42%
Return on equity (ttm)-46.40%

Income statement

Revenue (ttm)424k
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)1,166.70%
Gross profit (ttm)N/A
EBITDA -29.19M
Net income avi to common (ttm)-28.02M
Diluted EPS (ttm)-2.7200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)93.25M
Total cash per share (mrq)6.61
Total debt (mrq)214k
Total debt/equity (mrq)0.24%
Current ratio (mrq)12.73
Book value per share (mrq)6.29

Cash flow statement

Operating cash flow (ttm)-25.34M
Levered free cash flow (ttm)-12.25M